肥胖是体外氧合治疗失败的危险因素:系统回顾和荟萃分析。

IF 2.1 4区 医学 Q3 RESPIRATORY SYSTEM Canadian respiratory journal Pub Date : 2021-05-22 eCollection Date: 2021-01-01 DOI:10.1155/2021/9967357
Syed Arsalan A Zaidi, Kainat Saleem
{"title":"肥胖是体外氧合治疗失败的危险因素:系统回顾和荟萃分析。","authors":"Syed Arsalan A Zaidi, Kainat Saleem","doi":"10.1155/2021/9967357","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Obesity has been associated with an increased risk of respiratory complications and other systemic illnesses. Respiratory dynamics in an obese patient, combined with modified lung physiology of ARDS, present a significant challenge in managing obese patients with ARDS. Many physicians think of obesity as a relative contraindication to ECMO. We performed a meta-analysis to see the effect of obesity on weaning from ECMO and survival to hospital discharge.</p><p><strong>Methods: </strong>We searched online databases for studies on ECMO and obesity. The search yielded 49 citations in total; after extensive review, six studies were assessed and qualified to be included in the final analysis. Patients were stratified into BMI >30 kg/m<sup>2</sup> (obese) and BMI < 30 kg/m<sup>2</sup> (nonobese).</p><p><strong>Results: </strong>In meta-analysis, there was a total sample population of 1285 patients, with 466 in the obese group and 819 in the nonobese group. There was no significant difference in weaning from ECMO when compared between obese and nonobese patients, with a risk ratio of 1.03 and 95% confidence interval (CI) of 0.94-1.13 (heterogeneity: chi<sup>2</sup> = 7.44, df = 4 (<i>p</i>=0.11), <i>I</i> <sup>2</sup> = 46%). There was no significant difference in survival rates between obese and nonobese patients who were treated with ECMO during hospitalization, with a risk ratio of 1.04 and 95% CI of 0.86-1.25 (heterogeneity: Tau<sup>2</sup> 0.03, chi<sup>2</sup> = 14.61, df = 5 (<i>p</i>=0.01), <i>I</i> <sup>2</sup> = 66%).</p><p><strong>Conclusion: </strong>Our findings show no significant difference in survival and weaning from ECMO in obese vs. nonobese patients. ECMO therapy should not be withheld from obese patients, as obesity is not a contraindication to ECMO.</p>","PeriodicalId":9416,"journal":{"name":"Canadian respiratory journal","volume":"2021 ","pages":"9967357"},"PeriodicalIF":2.1000,"publicationDate":"2021-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164539/pdf/","citationCount":"10","resultStr":"{\"title\":\"Obesity as a Risk Factor for Failure to Wean from ECMO: A Systematic Review and Meta-Analysis.\",\"authors\":\"Syed Arsalan A Zaidi, Kainat Saleem\",\"doi\":\"10.1155/2021/9967357\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Obesity has been associated with an increased risk of respiratory complications and other systemic illnesses. Respiratory dynamics in an obese patient, combined with modified lung physiology of ARDS, present a significant challenge in managing obese patients with ARDS. Many physicians think of obesity as a relative contraindication to ECMO. We performed a meta-analysis to see the effect of obesity on weaning from ECMO and survival to hospital discharge.</p><p><strong>Methods: </strong>We searched online databases for studies on ECMO and obesity. The search yielded 49 citations in total; after extensive review, six studies were assessed and qualified to be included in the final analysis. Patients were stratified into BMI >30 kg/m<sup>2</sup> (obese) and BMI < 30 kg/m<sup>2</sup> (nonobese).</p><p><strong>Results: </strong>In meta-analysis, there was a total sample population of 1285 patients, with 466 in the obese group and 819 in the nonobese group. There was no significant difference in weaning from ECMO when compared between obese and nonobese patients, with a risk ratio of 1.03 and 95% confidence interval (CI) of 0.94-1.13 (heterogeneity: chi<sup>2</sup> = 7.44, df = 4 (<i>p</i>=0.11), <i>I</i> <sup>2</sup> = 46%). There was no significant difference in survival rates between obese and nonobese patients who were treated with ECMO during hospitalization, with a risk ratio of 1.04 and 95% CI of 0.86-1.25 (heterogeneity: Tau<sup>2</sup> 0.03, chi<sup>2</sup> = 14.61, df = 5 (<i>p</i>=0.01), <i>I</i> <sup>2</sup> = 66%).</p><p><strong>Conclusion: </strong>Our findings show no significant difference in survival and weaning from ECMO in obese vs. nonobese patients. ECMO therapy should not be withheld from obese patients, as obesity is not a contraindication to ECMO.</p>\",\"PeriodicalId\":9416,\"journal\":{\"name\":\"Canadian respiratory journal\",\"volume\":\"2021 \",\"pages\":\"9967357\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2021-05-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164539/pdf/\",\"citationCount\":\"10\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Canadian respiratory journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1155/2021/9967357\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"RESPIRATORY SYSTEM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian respiratory journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2021/9967357","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 10

摘要

目的:肥胖与呼吸系统并发症和其他全身性疾病的风险增加有关。肥胖患者的呼吸动力学,结合ARDS的肺生理变化,对肥胖合并ARDS患者的管理提出了重大挑战。许多医生认为肥胖是体外氧合的相对禁忌症。我们进行了一项荟萃分析,以观察肥胖对ECMO断奶和存活至出院的影响。方法:我们在网上数据库中检索ECMO与肥胖的研究。搜索总共产生了49次引用;经过广泛的审查,对六项研究进行了评估,并有资格纳入最终分析。将患者分为BMI bb0 ~ 30 kg/m2(肥胖)和BMI 2(非肥胖)。结果:meta分析共纳入1285例患者,其中肥胖组466例,非肥胖组819例。肥胖和非肥胖患者在ECMO脱机方面无显著差异,风险比为1.03,95%可信区间(CI)为0.94-1.13(异质性:chi2 = 7.44, df = 4 (p=0.11), i2 = 46%)。住院期间接受ECMO治疗的肥胖和非肥胖患者的生存率无显著差异,风险比为1.04,95% CI为0.86-1.25(异质性:Tau2 0.03, chi2 = 14.61, df = 5 (p=0.01), i2 = 66%)。结论:我们的研究结果显示,肥胖和非肥胖患者的ECMO生存率和断奶时间没有显著差异。肥胖患者不应拒绝ECMO治疗,因为肥胖不是ECMO的禁忌症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Obesity as a Risk Factor for Failure to Wean from ECMO: A Systematic Review and Meta-Analysis.

Purpose: Obesity has been associated with an increased risk of respiratory complications and other systemic illnesses. Respiratory dynamics in an obese patient, combined with modified lung physiology of ARDS, present a significant challenge in managing obese patients with ARDS. Many physicians think of obesity as a relative contraindication to ECMO. We performed a meta-analysis to see the effect of obesity on weaning from ECMO and survival to hospital discharge.

Methods: We searched online databases for studies on ECMO and obesity. The search yielded 49 citations in total; after extensive review, six studies were assessed and qualified to be included in the final analysis. Patients were stratified into BMI >30 kg/m2 (obese) and BMI < 30 kg/m2 (nonobese).

Results: In meta-analysis, there was a total sample population of 1285 patients, with 466 in the obese group and 819 in the nonobese group. There was no significant difference in weaning from ECMO when compared between obese and nonobese patients, with a risk ratio of 1.03 and 95% confidence interval (CI) of 0.94-1.13 (heterogeneity: chi2 = 7.44, df = 4 (p=0.11), I 2 = 46%). There was no significant difference in survival rates between obese and nonobese patients who were treated with ECMO during hospitalization, with a risk ratio of 1.04 and 95% CI of 0.86-1.25 (heterogeneity: Tau2 0.03, chi2 = 14.61, df = 5 (p=0.01), I 2 = 66%).

Conclusion: Our findings show no significant difference in survival and weaning from ECMO in obese vs. nonobese patients. ECMO therapy should not be withheld from obese patients, as obesity is not a contraindication to ECMO.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Canadian respiratory journal
Canadian respiratory journal 医学-呼吸系统
CiteScore
4.20
自引率
0.00%
发文量
61
审稿时长
6-12 weeks
期刊介绍: Canadian Respiratory Journal is a peer-reviewed, Open Access journal that aims to provide a multidisciplinary forum for research in all areas of respiratory medicine. The journal publishes original research articles, review articles, and clinical studies related to asthma, allergy, COPD, non-invasive ventilation, therapeutic intervention, lung cancer, airway and lung infections, as well as any other respiratory diseases.
期刊最新文献
Associations of Vitamin D With GPX4 and Iron Parameters in Chronic Obstructive Pulmonary Disease Patients: A Case-Control Study. Geographic Differences in Availability and Access to Care Services for Asthma and COPD: Case Study of Vancouver Coastal Health, British Columbia. Clinical Analysis of 32 Cases of Subglottic Benign Airway Stenosis Treated With Montgomery T Silicone Stent. Nomograms for Predicting High Hospitalization Costs and Prolonged Stay among Hospitalized Patients with pAECOPD. Gentiopicroside Ameliorates Sepsis-Induced Acute Lung Injury via Inhibiting Inflammatory Response.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1